micro-community-banner
Profile Image
  • Add Media
  • Saved

9mo

Did you know? Statins are linked to a 9–12% increased risk of new-onset diabetes, particularly with long-term, high-dose use and in patients with impaired glucose regulation. Still, their cardiovascular benefits usually outweigh this risk, prompting continued use in most at-risk populations.

Could statins’ effects on insulin release and sensitivity explain their role in glucose abnormalities?

Statins

Could statins’ effects on insulin release and sensitivity explain their role in glucose abnormalities?

Profile Image
  • Saved

9mo
infographic infographic 
Profile Image
  • Saved

9mo
Air pollution and atherosclerosis - PubMed

Air pollution and atherosclerosis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/40411956/

Air pollution is associated with considerable cardiovascular mortality and morbidity. The vascular disease atherosclerosis underlies many cardiovascular conditions, with atherosclerotic plaque rupture being a trigger for stroke and myocardial infarction....

 

Air pollution contributes significantly to atherosclerosis development and progression, increasing cardiovascular risks. This review highlights epidemiological links, biological mechanisms, and urges urgent action to mitigate pollution-related cardiovascular disease.

Profile Image
  • Saved

9mo
ADA 2025 Highlights: Obesity Therapies, Islet Cell Advances, and Oral GLP-1 Outcomes in T2D

At ADA 2025, Dr. Mark Atkinson (University of Florida Diabetes Institute) highlighted the systemic benefits of obesity-targeted therapies, including cardiometabolic and cognitive improvements, while noting concerns about implementation and potential muscle loss. Emerging advances in stem cell–derived islet transplantation for type 1 diabetes show promise in reducing insulin dependence. Dr. John Buse (University of North Carolina) presented SOUL trial data indicating that oral GLP-1 receptor agonist therapy reduced major adverse cardiovascular events—CV death, nonfatal MI, or stroke—by 14%, with additional reductions in limb complications in high-risk patients with type 2 diabetes.

Profile Image
  • Saved

9mo
Possible Involvement of Lysophospholipids in Severe Asthma as Novel Lipid Mediators - PubMed

Possible Involvement of Lysophospholipids in Severe Asthma as Novel Lipid Mediators - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/40001485/

In severe asthma, symptoms are unstable despite intensive treatment based on high doses of inhaled corticosteroids and on-demand use of oral corticosteroids. Although, recently, various biological agents related to Th2...

 

Severe asthma remains poorly controlled despite current therapies. Lysophospholipids, acting independently of Type 2 inflammation, may drive corticosteroid resistance and airway dysfunction, offering promising new targets for precision asthma treatment.

Profile Image